NEW YORK, Aug. 8 – Genomics Collaborative and ActivX Biosciences have initiated a joint program to identify proteins with potential as drug targets for colon cancer, Genomics Collaborative said on Wednesday.
Genomics Collaborative, which has assembled a large collection of human DNA, sera, and tissue samples linked to specific diseases, will supply clinical samples to ActivX for analysis. ActivX, meanwhile, will screen those samples for proteins associated with colon cancer by using its platform for synthesizing chemical probes that bind with active sites specific to whole protein families.
The companies did not disclose financial details or how they would share any intellectual property generated in the collaboration.
“By applying the power of our collective capabilities to extremely well-characterized colon cancer tissue, this partnership will position both companies to uncover promising new targets in this disease," Michael Pellini, CEO of Cambridge, Mass.-based Genomics Collaborative, said in a statement.
In July, San Diego-based ActivX announced the closing of a $20 million private placement that it said would help it hire new scientists to further develop its platform.